This topic contains a solution. Click here to go to the answer

Author Question: In a nonlinear problem, the rate of change of the objective function with respect to the right-hand ... (Read 121 times)

madam-professor

  • Hero Member
  • *****
  • Posts: 584
In a nonlinear problem, the rate of change of the objective function with respect to the right-hand side of a constraint is given by the
 a. slope of the contour line.
  b. local optimum.
  c. Reducing gradient.
  d. Lagrangian multiplier.

Question 2

What would be the value of the sum of squares due to regression (SSR) if the total sum of squares (SST) is 25.32 and the sum of squares due to error (SSE) is 6.89?
 a. 31.89 b. 19.32
  c. 18.43 d. 15.32



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

aburgess

  • Sr. Member
  • ****
  • Posts: 361
Answer to Question 1

d
RATIONALE: In a nonlinear problem, the rate of change of the objective function with respect to the right-hand side of a constraint is given by the Lagrangian multiplier.

Answer to Question 2

c
RATIONALE: The three quantities are related as SST = SSR + SSE. Substituting the values, we get SSR=18.43.





 

Did you know?

Women are two-thirds more likely than men to develop irritable bowel syndrome. This may be attributable to hormonal changes related to their menstrual cycles.

Did you know?

About 100 new prescription or over-the-counter drugs come into the U.S. market every year.

Did you know?

In most cases, kidneys can recover from almost complete loss of function, such as in acute kidney (renal) failure.

Did you know?

The human body's pharmacokinetics are quite varied. Our hair holds onto drugs longer than our urine, blood, or saliva. For example, alcohol can be detected in the hair for up to 90 days after it was consumed. The same is true for marijuana, cocaine, ecstasy, heroin, methamphetamine, and nicotine.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library